Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Hold” by Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned an average rating of “Hold” from the fourteen ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $4.3636.

Several research firms have recently commented on HCAT. Summit Redstone set a $5.00 price objective on shares of Health Catalyst in a research note on Friday, August 29th. Canaccord Genuity Group reduced their target price on shares of Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, August 29th. William Blair restated an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. KeyCorp reduced their price objective on Health Catalyst from $5.00 to $4.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company decreased their target price on Health Catalyst from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. XTX Topco Ltd purchased a new stake in Health Catalyst in the 1st quarter valued at $54,000. Primecap Management Co. CA grew its position in Health Catalyst by 3.8% during the 1st quarter. Primecap Management Co. CA now owns 2,005,116 shares of the company’s stock worth $9,083,000 after purchasing an additional 72,499 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Health Catalyst by 172.6% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 694,361 shares of the company’s stock valued at $3,145,000 after purchasing an additional 439,599 shares during the period. Invesco Ltd. increased its stake in Health Catalyst by 22.2% in the first quarter. Invesco Ltd. now owns 97,599 shares of the company’s stock valued at $442,000 after purchasing an additional 17,725 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of Health Catalyst in the first quarter valued at about $2,674,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Trading Down 1.1%

NASDAQ HCAT opened at $2.69 on Friday. The firm’s 50-day moving average is $2.84 and its two-hundred day moving average is $3.32. Health Catalyst has a 12 month low of $2.02 and a 12 month high of $8.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88. The stock has a market capitalization of $190.26 million, a P/E ratio of -1.69 and a beta of 1.72.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Monday, November 10th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.05 by $0.01. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.The business had revenue of $76.32 million during the quarter, compared to analyst estimates of $75.05 million. On average, sell-side analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.